[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337107-105":59,"doc-detail-337107-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","repurposing-anti-mesothelin-car-nk-immunotherapy-against-colorectal-cancer","Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer","","Colorectal cancer has widely variable outcomes and many patients fail to respond to standard treatments or develop resistance. The study evaluates repurposing CAR-based adoptive immunotherapy by targeting mesothelin (MSLN), aiming to avoid the significant adverse events seen with some CAR approaches. Researchers analyzed MSLN RNA in large CRC cohorts to find overexpressing models, generated NK-92 cells transduced with anti-MSLN CAR, and compared CAR-NK activity across in vitro and in vivo CRC and ovarian models, assessing efficacy by t-test and log-rank methods.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-anti-mesothelin-car-nk-immunotherapy-against-colorectal-cancer/337107/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-anti-mesothelin-car-nk-immunotherapy-against-colorectal-cancer/337107.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"Why repurpose anti-mesothelin CAR-NK immunotherapy for colorectal cancer?","Question",{"text":112,"@type":113},"Preclinical evidence supports targeting colorectal cancer subsets with high mesothelin levels using MSLN-CAR-based immunotherapy. The potential impact is amplified because frequently MSLN-overexpressing CRCs show worse prognosis and resistance to standard care.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},337107,1790183810,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Torchiaro et al.  \nJournal of Translational Medicine (2024) 22:1100 [https://doi.org/10.1186/s12967-024-05851-y](https://doi.org/10.1186/s12967-024-05851-y)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nRepurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer  \nErica Torchiaro1,2*†, Marco Cortese1,2†, Consalvo Petti 1,2, Marco Basirico’ 1, Federica Invrea 1, Alice D’Andrea 1,2, Letizia Franco 1, Dario Sangiolo2 and Enzo Medico1,2*  \nAbstract  \nBackground Colorectal cancer (CRC) is the third most common cancer worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond to standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however with significant adverse events. We therefore evaluated alternative CAR targets already tested in other tumour types and employed the natural killer cell line NK-92 for CAR transduction because of its more favourable toxicity profile.  \nMethods As an alternative antigen, we considered mesothelin (MSLN), the most represented target in CAR-based clinical studies for solid tumours. MSLN RNA expression was analysed in large series of CRC tumours (n = 640) and cell lines (n = 150), to evaluate its distribution and to identify MSLN-overexpressing models. NK-92 cells were transduced with anti-MSLN CAR, and subsequently sorted and cloned. Activity of CAR-NK-92 cells against target-expressing ovarian and CRC cells was assessed in vitro and in vivo. Statistical significance of efficacy was evaluated by t-test and logrank test.  \nResults Large-scale expression analysis highlighted that about 10% of CRCs overexpress MSLN at levels comparable to those of ovarian cancer, a typical target of MSLN-CAR-based therapy. Intriguingly, MSLN overexpression is more frequent in poor prognosis and KRAS/BRAF-mutant CRC. Lentiviral transduction of NK-92 cells with the MSLN-CAR, followed by sorting and cloning, led to the identification of one clone, MSLN. CAR. NK-92 . cl45, stably expressing the CAR and retaining the NK phenotype. As expected, the clone demonstrated significant in vitro and in vivo activity against ovarian cancer cells. When repurposed against models of CRC expressing high MSLN levels, it displayed comparable efficacy, both in vitro and in vivo. Specificity of the clone was confirmed by the absence of activity on control models with low or absent MSLN.  \nConclusions Our results provide preclinical evidence that a subset of colorectal cancers expressing high mesothelin levels can be effectively targeted by MSLN-CAR-based immunotherapy. The potential therapeutic impact of these findings is enhanced by the fact that frequently MSLN-overexpressing CRCs display worse prognosis and resistance to standard care.  \n†Erica Torchiaro and Marco Cortese contributed equally to this work.  \n*Correspondence: Erica Torchiaro[erica.torchiaro@ircc.it](erica.torchiaro@ircc.it)[ ](erica.torchiaro@ircc.it)Enzo Medico [enzo.medico@ircc.it](enzo.medico@ircc.it)  \n1 Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy  \n2 Department of Oncology, University of Turin, Candiolo, TO, Italy  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the ","cbCaiflFtyRpMRVN","https://ap.wps.com/l/cbCaiflFtyRpMRVN","pdf",1785962,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"Why repurpose anti-mesothelin CAR-NK immunotherapy for colorectal cancer?\",\"answer\":\"Preclinical evidence supports targeting colorectal cancer subsets with high mesothelin levels using MSLN-CAR-based immunotherapy. The potential impact is amplified because frequently MSLN-overexpressing CRCs show worse prognosis and resistance to standard care.\"}]","Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer | PDF",1790017725,33,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/431541b31fd3fcc16950ae8ccb88b206.webp",983,1305,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5a81ad91f9029933afebc6dc0894b25.webp",982,1304,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a41aeefa19f1d1ad935bddd960c6a035.webp",981,1303,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24a18799c682f5a9b6e6acee7c48c897.webp",980,1301]